Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077365 | 1.00 | CA2 (0.55) | CA2ALDH1A1NPSR1KDM4EALOX15 | |
| SCHEMBL1901250 | 1.00 | CA2 (0.55) | CA2ALDH1A1NPSR1KDM4EALOX15 | |
| SCHEMBL2748061 | 0.90 | CA2 (0.53) | CA2ALDH1A1NPSR1KDM4EALOX15 | |
| SCHEMBL20707263 | 0.89 | CA2 (0.51) | CA2ALDH1A1NPSR1KDM4EALOX15 | |
| SCHEMBL9152538 | 0.89 | CA2 (0.51) | CA2ALDH1A1NPSR1KDM4EALOX15 | |
| SCHEMBL1222790 | 0.83 | CA2 (0.73) | CA2ALDH1A1NPSR1KDM4EALOX15 | |
| SCHEMBL1416178 | 0.83 | CA2 (0.73) | CA2ALDH1A1NPSR1KDM4EALOX15 | |
| SCHEMBL849140 | 0.83 | CA2 (0.73) | CA2ALDH1A1NPSR1KDM4EALOX15 | |
| SCHEMBL2749426 | 0.83 | CA2 (0.59) | CA2ALDH1A1NPSR1KDM4EALOX15 | |
| SCHEMBL12359316 | 0.81 | CA2 (0.50) | CA2ALDH1A1NPSR1KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3878451-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A JAK-INHIBITING 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINE COMPOUND | Array Biopharma Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10189845-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
| WO-2016090285-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2015006740-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2010031713-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| WO-2009097578-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-06 | — | — | WO | disclosed |
| CN-101472904-A | Diazepan derivatives modulators of chemokine receptors | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | CN | disclosed |
| EP-2010506-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007122103-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
| EP-0055239-B1 | NOVEL DERIVATIVES OF GUANINE | Astra Läkemedel Aktiebolag (SE) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | CA2 4677/4885ALDH1A1 1084/4885NPSR1 584/4885 |
| US-20090305998-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | CA2 4094/4885ALDH1A1 1601/4885NPSR1 4385/4885 |
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | RTCB, IGF2BP2, SNRPE | CA2 4856/4885ALDH1A1 1611/4885NPSR1 753/4885 |
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CA2 3437/4885ALDH1A1 1526/4885NPSR1 2228/4885 |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CA2 3437/4885ALDH1A1 1526/4885NPSR1 2228/4885 |
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | CA2 680/4885ALDH1A1 2871/4885NPSR1 143/4885 |
| US-10189845-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | JAK1, JAK3, JAK2 | CA2 3437/4885ALDH1A1 1526/4885NPSR1 2228/4885 |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | JAK1, JAK3, JAK2 | CA2 3437/4885ALDH1A1 1526/4885NPSR1 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.